# A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

> **NCT00639691** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 48 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** omalizumab

## Key facts

- **NCT ID:** NCT00639691
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639691, "A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00639691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*